338 related articles for article (PubMed ID: 17875112)
1. Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol.
Kim JH; Byun HJ
J Clin Pharm Ther; 2007 Oct; 32(5):461-7. PubMed ID: 17875112
[TBL] [Abstract][Full Text] [Related]
2. Non-motor cognitive-perceptual dysfunction associated with drug-induced parkinsonism.
Kim JH; Byun HJ
Hum Psychopharmacol; 2009 Mar; 24(2):129-33. PubMed ID: 19204914
[TBL] [Abstract][Full Text] [Related]
3. Subjective cognitive dysfunction associated with drug-induced parkinsonism in schizophrenia.
Kim JH; Kim SY; Byun HJ
Parkinsonism Relat Disord; 2008; 14(3):239-42. PubMed ID: 17851106
[TBL] [Abstract][Full Text] [Related]
4. The relationship between akathisia and subjective tolerability in patients with schizophrenia.
Kim JH; Byun HJ
Int J Neurosci; 2010 Jul; 120(7):507-11. PubMed ID: 20583904
[TBL] [Abstract][Full Text] [Related]
5. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
6. Subjective emotional experience and cognitive impairment in drug-induced akathisia.
Kim JH; Lee BC; Park HJ; Ahn YM; Kang UG; Kim YS
Compr Psychiatry; 2002; 43(6):456-62. PubMed ID: 12439833
[TBL] [Abstract][Full Text] [Related]
7. Association of adverse drug effects with subjective well-being in patients with schizophrenia receiving stable doses of risperidone.
Kim JH; Kim MJ
Clin Neuropharmacol; 2009; 32(5):250-3. PubMed ID: 19620847
[TBL] [Abstract][Full Text] [Related]
8. The relationship of Akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone.
Seemüller F; Lewitzka U; Bauer M; Meyer S; Musil R; Schennach R; Riedel M; Doucette S; Möller HJ
Pharmacopsychiatry; 2012 Nov; 45(7):292-6. PubMed ID: 22614116
[TBL] [Abstract][Full Text] [Related]
9. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.
Csernansky JG; Mahmoud R; Brenner R;
N Engl J Med; 2002 Jan; 346(1):16-22. PubMed ID: 11777998
[TBL] [Abstract][Full Text] [Related]
10. Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia.
Kim JH; Kim SY; Ahn YM; Kim YS
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):301-5. PubMed ID: 16309807
[TBL] [Abstract][Full Text] [Related]
11. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.
Honer WG; Kopala LC; Rabinowitz J
J Psychopharmacol; 2005 May; 19(3):277-85. PubMed ID: 15888513
[TBL] [Abstract][Full Text] [Related]
12. Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia.
Fang M; Chen H; Li LH; Wu R; Li Y; Liu L; Ye M; Huang J; Zhu S; Wang G; Zhang Q; Zheng H; Zhang L; Wang B; Zhou J; Zhao JP
Int Clin Psychopharmacol; 2012 Mar; 27(2):107-13. PubMed ID: 22233697
[TBL] [Abstract][Full Text] [Related]
13. Extrapyramidal side effects and tolerability of risperidone: a review.
Owens DG
J Clin Psychiatry; 1994 May; 55 Suppl():29-35. PubMed ID: 7520906
[TBL] [Abstract][Full Text] [Related]
14. An open, randomized, comparative study of efficacy and safety of risperidone and haloperidol in schizophrenia.
Tamrakar SM; Nepal MK; Koirala NR; Sharma VD; Gurung CK; Adhikari SR
Kathmandu Univ Med J (KUMJ); 2006; 4(2):152-60. PubMed ID: 18603890
[TBL] [Abstract][Full Text] [Related]
15. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
16. A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database.
Fleischhacker WW; Lemmens P; van Baelen B
Pharmacopsychiatry; 2001 May; 34(3):104-10. PubMed ID: 11434401
[TBL] [Abstract][Full Text] [Related]
17. Akathisia and suicidal ideation in first-episode schizophrenia.
Seemüller F; Schennach R; Mayr A; Musil R; Jäger M; Maier W; Klingenberg S; Heuser I; Klosterkötter J; Gastpar M; Schmitt A; Schlösser R; Schneider F; Ohmann C; Lewitzka U; Gaebel W; Möller HJ; Riedel M;
J Clin Psychopharmacol; 2012 Oct; 32(5):694-8. PubMed ID: 22926606
[TBL] [Abstract][Full Text] [Related]
18. Predictors of subjective and objective quality of life in outpatients with schizophrenia.
Yamauchi K; Aki H; Tomotake M; Iga J; Numata S; Motoki I; Izaki Y; Tayoshi S; Kinouchi S; Sumitani S; Tayoshi S; Takikawa Y; Kaneda Y; Taniguchi T; Ishimoto Y; Ueno S; Ohmori T
Psychiatry Clin Neurosci; 2008 Aug; 62(4):404-11. PubMed ID: 18778437
[TBL] [Abstract][Full Text] [Related]
19. Neuroleptic-induced acute and chronic akathisia: a clinical comparison.
Kim JH; Jin YH; Kang UG; Ahn YM; Ha KS; Kim YS
Mov Disord; 2005 Dec; 20(12):1667-70. PubMed ID: 16078203
[TBL] [Abstract][Full Text] [Related]
20. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
